bioXXmed AG (DB: T5O)
Health Care · Biotechnology · DE
€0.83
-12.63% today · -58.5% 1Y
bioXXmed AG (DB: T5O) operates in the Biotechnology industry within the Health Care sector. The company is valued at $263.55K and employs 1 people.
Over the last twelve months the share price has lost 58.5%, trading between 0.01 and 2.60.
Tweenvest scores bioXXmed AG across four factors: quality 13/100, value 50/100, growth 100/100. Its strongest factor is growth.
T5O price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $263.55K
- Revenue (TTM)
- $19.64K
- P/E
- —
- EPS
- -1.34
- Dividend yield
- —
- Beta (5Y)
- 5.01
- 52-week high
- €2.60
- 52-week low
- €0.01
- Avg volume (3M)
- —
- Shares outstanding
- 271.87K
- Employees
- 1
- Next earnings
- —
About bioXXmed AG
CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.
- ISIN
- DE000A41YD32
- Founded
- 2000
- Listed since
- Dec 18, 2006
- Exchange
- Deutsche Boerse AG
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.